A Study of LY3298176 in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
Status:
Completed
Trial end date:
2017-06-26
Target enrollment:
Participant gender:
Summary
The main purposes of this study are to determine:
- The safety of LY3298176 and any side effects that might be associated with it.
- How much LY3298176 gets into the bloodstream and how long it takes the body to get rid
of it.
- How LY3298176 affects the levels of blood sugar.
This study includes 3 parts (A, B and C). Part A involves a single dose of LY3298176 taken as
a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in
duration, including screening. Parts B and C involve 4 doses of LY3298176 taken once weekly
(over 4 weeks) as a SC injection just under the skin and is approximately 12-14 weeks in
duration, including screening. Each participant will enroll in only one part.
This study is for research purposes only, and is not intended to treat any medical condition.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide Immunoglobulin Fc Fragments Tirzepatide